直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Federal Circuit Again Reverses Denial of Stay, a Nod to “Thumb on Scales of Justice” in Favor of Stays

December 05, 2014

Authored and Edited by Linda J. Thayer; Aaron L. Parker

On November 20, 2014, in Versata Software, Inc. v. Callidus Software, Inc., No. 2014-1468, the Federal Circuit reversed a Delaware district court’s denial of a stay pending CBM review. The Court noted that although it had authority under AIA § 18(b)(2), to review the decision de novo, it must be reversed even under the traditional abuse of discretion standard.

The Federal Circuit considered the district court’s application of the four factors of AIA § 18(b)(1) when deciding whether to grant a stay: (A) whether a stay will simplify the issues in litigation; (B) stage of litigation; (C) undue prejudice to nonmoving party or clear tactical advantage for moving party; and (D) whether a stay will reduce the burden of litigation on the parties and the court.

The Federal Circuit found that the district court erred in not granting a stay as to two of the three asserted patents because some of the asserted dependent claims were not the subject of an instituted CBM review at the time of the filing of the motion for stay. Citing VirtualAgility Inc. v. Salesforce.com, Inc., 759 F.3d 1307 (Fed. Cir. 2014), the Court reiterated that “[s]tays can be warranted even when a CBM proceeding does not address all asserted patents, claims, or invalidity defenses.” While the Court also took judicial notice that the PTAB had since instituted CBM review on the remaining claims of the two patents, which meant that all asserted claims would be under review, the Court found the PTAB’s review of the independent claims, and some of the asserted dependent claims, would necessarily simplify the issues and thus factor (A) favored a stay.

The Court reiterated that the stage of the litigation - factor (B) - as of the date of filing of the motion is most relevant, but called it “entirely appropriate” to wait for the PTAB’s decision on institution and not “ignore advances in the litigation” up to that date. The Court found, however, that even this factor strongly favored a stay, because, although discovery had begun, “both fact and expert discovery remained ongoing, and the Markman hearing and trial date were still well over a year away.”

It was reversible error for the district court to consider Callidus’ filing of preliminary motions as weighing against a stay when evaluating factors (C) and (D). Non-frivolous motions to transfer and dismiss for failure to state a claim did not constitute “undue prejudice” or “clear tactical advantage” as litigants are “within their rights” to use these tools in litigation. Even if filing these motions had “increased the burdens of litigation, the correct test is whether a stay will “indeed reduce the future burdens of litigation.”

Tags

District Court, United States Court of Appeals for the Federal Circuit (CAFC)

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Aaron L. Parker
Partner
Washington, DC
+1 202 408 4387
Email

Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Reception

12th Annual Georgia Asian Pacific American Bar Association Gala

May 21, 2026

Atlanta

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP